SIBP-A10 injection for adults with advanced malignant tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label phase 1 study uses dose escalation, dose expansion, and indication expansion stages to evaluate SIBP-A10 given by injection in adults with advanced metastatic tumors. Planned doses range from 0.5 to 15 mg/kg with an initial 3+3 escalation design, followed by selected dose expansions (about 20 subjects per expansion cohort) and four indication-specific expansion cohorts (about 40 subjects each) to define a phase II recommended dose. Key measures include safety, tolerability, pharmacokinetics, immunogenicity, impact on QT/QTc interval, preliminary anti-tumor activity, and exploratory biomarker analyses. Enrollment requires measurable disease, adequate organ function, ECOG 0–1, and willingness to provide tumor tissue.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Voluntarily participate in this study and sign an informed consent form;
* Age range of 18 to 75 years old (including boundary values), gender not limited;
* The clinical diagnosis of enrolled subjects should meet the conditions specified in the protocol:
* There must be at least one measurable lesion as the target lesion;
* Backfilling queue during dose escalation stage, dose expansion stage, and indication expansion stage: able to provide tumor tissue samples that meet the requirements of the protocol or undergo tumor biopsy during screening, or provide testing reports issued by legitimate testing institutions that meet the requirements;
* I have not received any medication targeting Siglec-15 in the past;
* The Eastern Cooperative Oncology Group (ECOG) physical fitness score ranges from 0 to 1;
* Expected survival period ≥ 3 months;
* During the screening period, the main organ functions were basically normal;
* During the screening period, women of childbearing age had negative blood pregnancy tests, and reproductive age subjects (including male subjects) had no pregnancy plans during the trial period and within 6 months after the last dose, and voluntarily took effective contraceptive measures.

Exclusion Criteria:

* The subject has the following tumors:

  * The subject has had other malignant tumors that have not healed within the past 5 years;
  * Subjects with meningeal metastases;
  * Subjects with active brain metastases;
* For anti-tumor subjects with a history of past treatment or surgery that does not comply with the protocol, or who have received treatment that does not comply with the protocol during the planned trial period
* Previous medical history or laboratory non-compliance with protocol requirements
* According to the researchers' assessment, the screening period is accompanied by severe, progressive, or uncontrolled non-tumor diseases, and it has been determined by the researchers that participating in the study would increase the risk for the subjects.
* According to the investigator's judgment, there are concomitant diseases (including but not limited to hypertension, diabetes, active infection, etc. that cannot be controlled by drugs) that seriously endanger the patient's safety or affect the patient's completion of the study
* Researchers determine that there are uncontrollable ascites, pleural effusion, or pericardial effusion, or those who have undergone ≥ 2 serosal drainage within 2 weeks prior to the first administration;
* Before starting treatment, the patient has not yet recovered to ≤ grade 1 from the toxic effects of previous treatments (including previous immunotherapy) and/or complications of previous surgical interventions.
* Individuals with a history of severe allergies to protein products, CHO cell products, other recombinant human or humanized antibodies, or components of the investigational drug;
* Pregnant and lactating women;
* Researchers believe that subjects who are not suitable to participate in this clinical study due to other reasons.

Where it's running

• Zhongshan Hospital Affiliated to Dalian University
  Dalian, Liaoning, China Recruiting

Study contacts

• Principal investigator: Li Zhang, Docter — Shanghai Institute Of Biological Products
• Study coordinator: Dan dan Chen, Master
• Email: ddchen.sh@sinopharm.com
• Phone: +862162800991

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• GW01-200 tablets in people with advanced cancers

  This early-phase study tests GW01-200 tablets in adults with advanced solid tumors or blood cancers to see if they are safe and how they behave in the body.

  Recruiting at 3 sites Phase 1 Groovy Medicine (Hangzhou) Ltd. · Beijing, Beijing Municipality and 2 other locations · NCT07629258

• AL58805 treatment for people with advanced solid tumors.

  This Phase I dose-escalation trial will test different oral doses of AL58805 in people with advanced solid tumors who have exhausted standard treatment options.

  Recruiting Phase 1 Advenchen Laboratories, LLC · Changsha, Hunan · NCT07179081

• Testing MDX2004 at increasing doses in adults with advanced tumors

  This will test whether different doses of the experimental drug MDX2004 are safe and can shrink tumors in adults with advanced or metastatic cancer.

  Recruiting at 6 sites Phase 1/2 ModeX Therapeutics, An OPKO Health Company · Liverpool, New South Wales and 5 other locations · NCT07110584

• Personalized neoantigen vaccine combined with radiotherapy for advanced tumors

  This study is testing a personalized vaccine made from a patient's own tumor cells combined with radiotherapy to see if it can help people with advanced tumors that haven't responded to standard treatments.

  Recruiting Phase 2 The University of Hong Kong-Shenzhen Hospital · Shenzhen, Guangdong and 1 other locations · NCT06314087

• Evaluating CS23546 for patients with advanced tumors

  This study is testing a new treatment called CS23546 to see if it's safe and how well it works for people with advanced tumors.

  Recruiting Phase 1 Chipscreen Biosciences, Ltd. · Guangzhou · NCT06245122

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.